Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Treasury Shares (2023 - 2025)

InMed Pharmaceuticals' Treasury Shares history spans 3 years, with the latest figure at $3.7 million for Q4 2025.

  • For Q4 2025, Treasury Shares rose 7826.09% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 7826.09%, while the annual FY2025 figure was $4.5 million, 734.35% up from the prior year.
  • Treasury Shares reached $3.7 million in Q4 2025 per INM's latest filing, down from $3.9 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $13.2 million in Q1 2024 to a low of $42096.0 in Q1 2025.
  • Average Treasury Shares over 3 years is $2.7 million, with a median of $551773.5 recorded in 2023.
  • The largest YoY upside for Treasury Shares was 7826.09% in 2025 against a maximum downside of 99.68% in 2025.
  • A 3-year view of Treasury Shares shows it stood at $559267.0 in 2023, then tumbled by 91.56% to $47176.0 in 2024, then soared by 7826.09% to $3.7 million in 2025.
  • Per Business Quant, the three most recent readings for INM's Treasury Shares are $3.7 million (Q4 2025), $3.9 million (Q3 2025), and $4.5 million (Q2 2025).